Dapagliflozin's HFpEF Win; Angiograms of the HIV+; Side Effects of PCSK9 Inhibitors?

(MedPage Today) -- For heart failure patients with mildly reduced or preserved ejection fraction in the DELIVER trial, dapagliflozin (Farxiga) helped reduce the risk of cardiovascular death and worsening heart failure, AstraZeneca announced, paving...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news